Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

Joong Won Park, Deepak Amarapurkar, Yee Chao, Pei Jer Chen, Jean Francois H Geschwind, Khean Lee Goh, Kwang Hyub Han, Masatoshi Kudo, Han Chu Lee, Rheun Chuan Lee, Laurentius A. Lesmana, Ho Yeong Lim, Seung Woon Paik, Ronnie T. Poon, Chee Kiat Tan, Tawesak Tanwandee, Gaojun Teng, Ann Lii Cheng

Research output: Contribution to journalArticle

Abstract

Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens.

Original languageEnglish (US)
Pages (from-to)327-337
Number of pages11
JournalLiver International
Volume33
Issue number3
DOIs
StatePublished - 2013

Fingerprint

Hepatocellular Carcinoma
Neoplasm Staging
Expert Testimony
Liver Neoplasms
Tumor Burden
Liver Diseases
Therapeutics
Neoplasm Metastasis
Safety
Survival
Population
Neoplasms

Keywords

  • Combination therapy
  • Hepatocellular carcinoma
  • Sorafenib
  • TACE

ASJC Scopus subject areas

  • Hepatology

Cite this

Park, J. W., Amarapurkar, D., Chao, Y., Chen, P. J., Geschwind, J. F. H., Goh, K. L., ... Cheng, A. L. (2013). Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver International, 33(3), 327-337. https://doi.org/10.1111/liv.12083

Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). / Park, Joong Won; Amarapurkar, Deepak; Chao, Yee; Chen, Pei Jer; Geschwind, Jean Francois H; Goh, Khean Lee; Han, Kwang Hyub; Kudo, Masatoshi; Lee, Han Chu; Lee, Rheun Chuan; Lesmana, Laurentius A.; Lim, Ho Yeong; Paik, Seung Woon; Poon, Ronnie T.; Tan, Chee Kiat; Tanwandee, Tawesak; Teng, Gaojun; Cheng, Ann Lii.

In: Liver International, Vol. 33, No. 3, 2013, p. 327-337.

Research output: Contribution to journalArticle

Park, JW, Amarapurkar, D, Chao, Y, Chen, PJ, Geschwind, JFH, Goh, KL, Han, KH, Kudo, M, Lee, HC, Lee, RC, Lesmana, LA, Lim, HY, Paik, SW, Poon, RT, Tan, CK, Tanwandee, T, Teng, G & Cheng, AL 2013, 'Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)', Liver International, vol. 33, no. 3, pp. 327-337. https://doi.org/10.1111/liv.12083
Park, Joong Won ; Amarapurkar, Deepak ; Chao, Yee ; Chen, Pei Jer ; Geschwind, Jean Francois H ; Goh, Khean Lee ; Han, Kwang Hyub ; Kudo, Masatoshi ; Lee, Han Chu ; Lee, Rheun Chuan ; Lesmana, Laurentius A. ; Lim, Ho Yeong ; Paik, Seung Woon ; Poon, Ronnie T. ; Tan, Chee Kiat ; Tanwandee, Tawesak ; Teng, Gaojun ; Cheng, Ann Lii. / Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). In: Liver International. 2013 ; Vol. 33, No. 3. pp. 327-337.
@article{730092a9e98f4cffb070bf87088d4de9,
title = "Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)",
abstract = "Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens.",
keywords = "Combination therapy, Hepatocellular carcinoma, Sorafenib, TACE",
author = "Park, {Joong Won} and Deepak Amarapurkar and Yee Chao and Chen, {Pei Jer} and Geschwind, {Jean Francois H} and Goh, {Khean Lee} and Han, {Kwang Hyub} and Masatoshi Kudo and Lee, {Han Chu} and Lee, {Rheun Chuan} and Lesmana, {Laurentius A.} and Lim, {Ho Yeong} and Paik, {Seung Woon} and Poon, {Ronnie T.} and Tan, {Chee Kiat} and Tawesak Tanwandee and Gaojun Teng and Cheng, {Ann Lii}",
year = "2013",
doi = "10.1111/liv.12083",
language = "English (US)",
volume = "33",
pages = "327--337",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC)

AU - Park, Joong Won

AU - Amarapurkar, Deepak

AU - Chao, Yee

AU - Chen, Pei Jer

AU - Geschwind, Jean Francois H

AU - Goh, Khean Lee

AU - Han, Kwang Hyub

AU - Kudo, Masatoshi

AU - Lee, Han Chu

AU - Lee, Rheun Chuan

AU - Lesmana, Laurentius A.

AU - Lim, Ho Yeong

AU - Paik, Seung Woon

AU - Poon, Ronnie T.

AU - Tan, Chee Kiat

AU - Tanwandee, Tawesak

AU - Teng, Gaojun

AU - Cheng, Ann Lii

PY - 2013

Y1 - 2013

N2 - Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens.

AB - Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens.

KW - Combination therapy

KW - Hepatocellular carcinoma

KW - Sorafenib

KW - TACE

UR - http://www.scopus.com/inward/record.url?scp=84984588811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984588811&partnerID=8YFLogxK

U2 - 10.1111/liv.12083

DO - 10.1111/liv.12083

M3 - Article

C2 - 23331661

AN - SCOPUS:84984588811

VL - 33

SP - 327

EP - 337

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 3

ER -